FDMT vs. AVBP, COGT, OCS, BCYC, DNA, IMNM, AVDL, CVAC, CDMO, and NUVB
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Oculis (OCS), Bicycle Therapeutics (BCYC), Ginkgo Bioworks (DNA), Immunome (IMNM), Avadel Pharmaceuticals (AVDL), CureVac (CVAC), Avid Bioservices (CDMO), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry.
4D Molecular Therapeutics vs.
4D Molecular Therapeutics (NASDAQ:FDMT) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking.
4D Molecular Therapeutics received 35 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 66.67% of users gave 4D Molecular Therapeutics an outperform vote.
In the previous week, 4D Molecular Therapeutics had 5 more articles in the media than ArriVent BioPharma. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.95 beat 4D Molecular Therapeutics' score of 0.52 indicating that ArriVent BioPharma is being referred to more favorably in the news media.
99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
4D Molecular Therapeutics presently has a consensus target price of $32.13, suggesting a potential upside of 592.35%. ArriVent BioPharma has a consensus target price of $38.00, suggesting a potential upside of 40.38%. Given 4D Molecular Therapeutics' higher possible upside, equities analysts clearly believe 4D Molecular Therapeutics is more favorable than ArriVent BioPharma.
ArriVent BioPharma has lower revenue, but higher earnings than 4D Molecular Therapeutics.
4D Molecular Therapeutics' return on equity of -28.00% beat ArriVent BioPharma's return on equity.
Summary
4D Molecular Therapeutics beats ArriVent BioPharma on 9 of the 13 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FDMT) was last updated on 2/22/2025 by MarketBeat.com Staff
Free FDMT Stock Alerts